

Fabio S Macaluso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/61380/publications.pdf>

Version: 2024-02-01

92
papers

2,077
citations

236612

25
h-index

276539

41
g-index

92
all docs

92
docs citations

92
times ranked

3672
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	0.6	201
2	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	3.6	183
3	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	1.1	123
4	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014, 59, 1692-1705.	3.6	75
5	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011, 31, 507-515.	1.9	70
6	Cardiovascular diseases and HCV infection: a simple association or more?. <i>Gut</i> , 2014, 63, 369-375.	6.1	67
7	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	1.8	67
8	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	1.4	66
9	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , 2013, 8, 13-22.	1.0	61
10	Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 486-493.	1.0	49
11	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014, 46, 1116-1120.	0.4	44
12	Psoriasis and Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2019, 37, 451-457.	0.8	41
13	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e31-e31.	0.5	40
14	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , 2020, 52, 1222-1227.	0.4	38
15	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 182-189.	0.9	35
16	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 675-681.	0.4	34
17	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	1.8	33
18	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	1.4	33

#	ARTICLE	IF	CITATIONS
19	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 89-98.	1.4	31
20	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1805-1812.	0.9	30
21	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor- α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 209-217.	0.6	30
22	Serum γ -glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165.	1.1	29
23	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013, 5, 685.	0.8	29
24	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 193-200.	1.8	28
25	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017, 74, 433-441.	1.7	28
26	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. <i>BioMed Research International</i> , 2013, 2013, 1-12.	0.9	26
27	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IGC-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
28	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	21
29	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multicentre study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1045-1055.	1.6	21
30	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020, 37, 383-392.	1.3	20
31	Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. <i>Liver International</i> , 2012, 32, 1443-1450.	1.9	19
32	PNPLA3 rs738409/748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 939-948.	1.9	18
33	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 936-942.	0.4	17
34	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	0.9	17
35	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF α Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 394-401.	0.9	16
36	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1292-1298.	0.4	16

#	ARTICLE	IF	CITATIONS
37	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020, 52, 1461-1466.	0.4	16
38	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 174-182.	1.0	15
39	<i><i><sc>TM</sc>6<sc>SF</sc>2</i></i> rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	1.9	15
40	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , 2017, 97, 1-3.	1.6	15
41	Ustekinumab in Crohn's disease: Real world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021, 5, 364-370.	0.7	15
42	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.4	14
43	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 105-111.	1.4	14
44	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3041-3049.	1.4	14
45	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	2.4	13
46	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 433-440.	1.2	13
47	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110106.	1.4	13
48	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	0.6	13
49	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 175-184.	1.4	12
50	Vaccinations in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1539-1545.	0.4	12
51	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1102-1106.	0.6	11
52	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. <i>Digestive and Liver Disease</i> , 2019, 51, 1270-1274.	0.4	11
53	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , 2016, 151, 211-212.	0.6	9
54	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 696.	0.8	9

#	ARTICLE	IF	CITATIONS
55	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 217-221.	0.9	9
56	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 310-311.	1.9	8
57	Letter: SPOSIB SB2â€™a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 234-236.	1.9	8
58	Effectiveness of Ustekinumab on Crohnâ€™s Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1381-1384.	1.4	8
59	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 203-223.	1.4	8
60	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 428-439.	0.4	8
61	Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. <i>Digestive and Liver Disease</i> , 2022, 54, 629-634.	0.4	8
62	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1451-1451.	0.6	7
63	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 1304-1309.	0.4	7
64	Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. <i>Digestive and Liver Disease</i> , 2022, 54, 183-191.	0.4	7
65	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. <i>Digestive and Liver Disease</i> , 2016, 48, 1506-1509.	0.4	6
66	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-Î± inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017, 49, 157-162.	0.4	6
67	Risk of Pneumonia Caused by <i>Pneumocystis jirovecii</i> in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 571-572.	2.4	6
68	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. <i>Gastroenterology</i> , 2021, 160, 1877-1878.	0.6	6
69	Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1040-1041.	1.9	5
70	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.4	5
71	Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. <i>World Journal of Hepatology</i> , 2013, 5, 288.	0.8	5
72	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019, 47, 409-415.	2.3	4

#	ARTICLE	IF	CITATIONS
73	Rescue Therapy with Intensive Vedolizumab Optimization in a Seventeen-Year-Old Girl with Acute Severe Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2470-2471.	1.1	4
74	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2020, 21, 247-255.	0.7	4
75	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 336.	0.8	4
76	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016, 16, e31681.	0.1	4
77	Antimitochondrial antibody α M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. <i>Hepatology Research</i> , 2012, 42, 428-432.	1.8	3
78	Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1257-1257.	1.4	3
79	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018, 50, 734-736.	0.4	3
80	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e51-e52.	0.9	3
81	Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. <i>Future Microbiology</i> , 2015, 10, 977-988.	1.0	2
82	Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1019-1020.	1.9	2
83	Letter: psoriasiform eruption during vedolizumab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 342-343.	1.9	2
84	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 291-297.	2.2	2
85	Ozanimod for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2022, 386, 194-195.	13.9	2
86	Letter: propensity score α handle with care. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 360-361.	1.9	2
87	The key role of colonoscopy at 6 months from ileocolonic resection in Crohn's disease patients. <i>Digestive and Liver Disease</i> , 2021, 53, 517-518.	0.4	1
88	Letter: mesalazine α a safe drug with rare serious adverse events. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1210-1211.	1.9	1
89	Epidemiological trends in pediatric inflammatory bowel disease: The precious contribution of the registries promoted by scientific societies. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	1
90	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 11356-11364.	0.5	1

#	ARTICLE	IF	CITATIONS
91	The VERSIFY Trial: What About Ultrasound Assessment?. <i>Gastroenterology</i> , 2020, 158, 1176-1177.	0.6	0
92	Reply to: "Multi-dermatomal herpes zoster in a young patient with Crohn's disease on thiopurine therapy: Need for reconsidering vaccine recommendations". <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0